Am. J. Respir. Crit. Care Med., Volume 162, Number 1, July 2000, 14-20

The Use of Cylexin (CY-1503) in Prevention of Reperfusion Lung Injury in Patients Undergoing Pulmonary Thromboendarterectomy

KIM M. KERR, WILLIAM R. AUGER, JAMES J. MARSH, ROBERTA M. COMITO, REBEKAH L. FEDULLO, GERARD J. SMITS, DAVID P. KAPELANSKI, PETER F. FEDULLO, RICHARD N. CHANNICK, STUART W. JAMIESON, and KENNETH M. MOSER

Division of Pulmonary and Critical Care Medicine and Division of Cardiothoracic Surgery, University of California, San Diego; and Cytel Corporation, San Diego, California

Pulmonary thromboendartectomy (PTE) for chronic thromboembolic pulmonary hypertension may be complicated by reperfusion lung injury. This has previously been demonstrated to be neutrophil-mediated. We postulated that blocking selectin-mediated adhesion of neutrophils to the endothelium with Cylexin (CY-1503) would prevent reperfusion lung injury in this patient population. In this double-blind, randomized, placebo-controlled, parallel study, 26 patients received Cylexin the day of surgery and 25 received placebo. Significantly fewer patients in the treated group (31%) compared with the placebo group (60%) developed lung injury (p = 0.036). However, the average number of days of mechanical ventilation, days in the intensive care unit (ICU) and hospital, as well as mortality were not significantly different between the treatment groups. Those with reperfusion lung injury had significantly elevated percent neutrophils, total protein, and soluble P-selectin in bronchoalveolar lavage fluid compared with those without lung injury. We conclude that reperfusion lung injury after PTE is a high-permeability lung injury and its incidence can be reduced by the administration of Cylexin on the day of surgery.

This article has been cited by other articles:

				P. A. Thistlethwaite, M. M. Madani, A. D. Kemp, M. Hartley, W. R. Auger, and S. W. Jamieson Venovenous Extracorporeal Life Support After Pulmonary Endarterectomy: Indications, Techniques, and Outcomes Ann. Thorac. Surg., December 1, 2006; 82(6): 2139 - 2145. [Abstract] [Full Text] [PDF]

				B. Ma, J. L. Simala-Grant, and D. E. Taylor Fucosylation in prokaryotes and eukaryotes Glycobiology, December 1, 2006; 16(12): 158R - 184R. [Abstract] [Full Text] [PDF]

				A. Hansen, A. Kumar, D. Wolf, K. Frankenbergerova, A. Filusch, M.-L. Gross, S. Mueller, H. Katus, and H. Kuecherer Evaluation of cardioprotective effects of recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography J. Am. Coll. Cardiol., August 18, 2004; 44(4): 887 - 891. [Abstract] [Full Text] [PDF]

				R. L. Doyle, D. McCrory, R. N. Channick, G. Simonneau, and J. Conte Surgical Treatments/Interventions for Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 63S - 71S. [Abstract] [Full Text] [PDF]

				S. Teng, S. Kurata, I. Katoh, G. S. Georgieva, T. Nosaka, C. Mitaka, and T. Imai Cytokine mRNA expression in unilateral ischemic-reperfused rat lung with salt solution supplemented with low-endotoxin or standard bovine serum albumin Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L137 - L142. [Abstract] [Full Text] [PDF]

				J. Zagorski, J. Debelak, M. Gellar, J. A. Watts, and J. A. Kline Chemokines Accumulate in the Lungs of Rats with Severe Pulmonary Embolism Induced by Polystyrene Microspheres J. Immunol., November 15, 2003; 171(10): 5529 - 5536. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]